Duration: CME/CE Points: Author(s):
CME : 0.75

Neurology: A Phase 3 Randomized Placebo-Controlled Trial of Tadalafil for Duchenne Muscular Dystrophy is organized by American Academy of Neurology (AAN) and will be held during Oct 24, 2017 - Oct 24, 2020.

The target audience for this medical event is physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine. This CME Conference has been approved for a maximum of 0.75 AMA PRA Category 1 Credits.

Conference Objectives are :

Upon completion of the article by Victor et al, the participant should be able to:
• Describe the effects of tadalafil on ambulatory performance as measured by the 6-minute walk distance (6MWD) compared to placebo observed in this study.
• Discuss the effects of tadalafil on secondary and exploratory outcomes, including quality of life and upper limb performance, used in this study.
• Describe the rates of adverse effects seen with tadalafil treatment (low- or high-dose) compared with placebo observed in this study.

Additional details will be posted as soon as they are available.

Target Audience

Neurology, Pediatrics, Genetics


Activity Fee : Fee Details will be updated soon


Neurology, Pediatrics, Genetics

Onsite to Virtual Conference

Market your online event to Million plus Healthcare professionals.